Livforsakringsbolaget Skandia’s Nektar Therapeutics NKTR Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-100	Closed	-$27K	–	662
2019 Q3	$27K	Hold	100	–	–	﹤0.01%	643
2019 Q2	$53K	Hold	100	–	–	0.01%	596
2019 Q1	$50K	Hold	100	–	–	0.01%	606
2018 Q4	$49K	Hold	100	–	–	0.01%	601
2018 Q3	$91K	Sell	100 -87	-47%	-$74.3K	0.01%	568
2018 Q2	$137K	Buy	+187	New	+$216K	0.01%	604

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Livforsakringsbolaget Skandia's NKTR Position: Q4 2019 in Review

Livforsakringsbolaget Skandia sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 100 shares — an estimated $27K sold.

Livforsakringsbolaget Skandia first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $137K in Q2 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

Livforsakringsbolaget Skandia reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 100 Nektar Therapeutics shares in Q4 2019, an estimated $27K.
Livforsakringsbolaget Skandia first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
Livforsakringsbolaget Skandia's Nektar Therapeutics position peaked at $137K in Q2 2018.
281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2019, filed 28 Jan 2020.